VBI Vaccines has published pre-clinical results of its triple candidate Covid-19 programme – VBI-2900 – and has now announced which two candidates will be progressing into Phase I/II studies.

The company is expected to advance VBI-2901, which is a a trivalent pan-coronavirus vaccine candidate against Covid-19, SARS and MERS, and VBI-2902, a monovalent vaccine targeting SARS-CoV-2, the virus which causes Covid-19, into clinical trials by the end of 2020. VBI believes they have the potential to be single dose vaccines.

VBI president and CEO Jeff Baxter commented: “We are excited to announce these impressive pre-clinical data, which we believe clearly support the advancement of the two vaccine candidates, VBI-2901 and VBI-2902, into human clinical studies around the end of the year.

“An effective solution to the ongoing Covid-19 pandemic will require a vaccine that is capable of providing robust protection, quickly.

“Based on the data seen to-date, we believe the VBI-2900 program has the potential to be administered as a one-dose vaccine regimen at human doses ranging from 2-5mcg, and, further, VBI-2901 may offer increased breadth of reactivity across a broader range of coronaviruses.

“We are very encouraged by these results and remain deeply committed to addressing this devastating public health crisis.”

VBI has been collaborating with the National Research Council of Canada on a pan coronavirus vaccine since April. The company’s subsidiary Variation BioTechnologies has also received CAD$56m from the Canadian government to support the VBI-2900 programme.